Related references
Note: Only part of the references are listed.Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy
Wen Liu et al.
JOURNAL OF IMMUNOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
New N-(1,3,4-thiadiazol-2-yl)furan-2-carboxamide derivatives as potential inhibitors of the VEGFR-2
Mohamed H. Hekal et al.
BIOORGANIC CHEMISTRY (2021)
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
Anwaar Saeed et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold
De-pu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Regulation of VEGFR Signalling in Lymphatic Vascular Development and Disease: An Update
Genevieve A. Secker et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Xiaomin Cai et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Oligometastatic Disease and Local Therapies A Medical Oncology Perspective
Navid Hafez et al.
CANCER JOURNAL (2020)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Michael Platten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Xiaofeng Chen et al.
ONCOLOGIST (2019)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation
Heba T. Abdel-Mohsen et al.
ARCHIV DER PHARMAZIE (2019)
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
Ute F. Rohrig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Mingxia Zhao et al.
ACTA PHARMACEUTICA SINICA B (2019)
Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development
Mayanne M. T. Zhu et al.
CURRENT ONCOLOGY REPORTS (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities
Jae Eun Cheong et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2018)
Progress in the treatment of solid tumors with apatinib: a systematic review
Deze Zhao et al.
ONCOTARGETS AND THERAPY (2018)
Targeting the IDO1 pathway in cancer: from bench to bedside
Ming Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Gene silencing of indoleamine 2,3-dioxygenase hinders tumor growth through angiogenesis inhibition
Jinfeng Pan et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health
Igor Cervenka et al.
SCIENCE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Arpita Mondal et al.
EBIOMEDICINE (2016)
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data
Patrick A. Ott et al.
FRONTIERS IN ONCOLOGY (2015)
Apatinib for the treatment of gastric cancer
Ruixuan Geng et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
Ivan Theate et al.
CANCER IMMUNOLOGY RESEARCH (2015)
APATINIB: A PROMISING ORAL ANTIANGIOGENIC AGENT IN THE TREATMENT OF MULTIPLE SOLID TUMORS
A. J. Scott et al.
DRUGS OF TODAY (2015)
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Xichun Hu et al.
BMC CANCER (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Tryptophan metabolism, from nutrition to potential therapeutic applications
Nathalie Le Floc'h et al.
AMINO ACIDS (2011)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Indoleamine 2,3-Dioxygenase Tissue Distribution and Cellular Localization in Mice: Implications for Its Biological Functions
Xiangchen Dai et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2010)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Vascular endothelial growth factor family of ligands and receptors: Review
Zaher K. Otrock et al.
BLOOD CELLS MOLECULES AND DISEASES (2007)
Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action
J Folkman
EXPERIMENTAL CELL RESEARCH (2006)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
MJ Karkkainen et al.
ONCOGENE (2000)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Share Paper
